Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. China Isotope & Radiation's Revenue for the
six
months ended in Dec. 2025 was €525.0 Mil. China Isotope & Radiation's average Accounts Receivable for the
six
months ended in Dec. 2025 was €595.0 Mil.
Hence, China Isotope & Radiation's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.88.
China Isotope & Radiation (FRA:5IR) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
China Isotope & Radiation Receivables Turnover Related Terms
China Isotope & Radiation Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation Receivables Turnover Chart
FRA:5IR vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, China Isotope & Radiation's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Isotope & Radiation Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where China Isotope & Radiation's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation (FRA:5IR) has a Receivables Turnover of 0.88 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on China Isotope & Radiation and its competitors. According to the industry distribution chart, China Isotope & Radiation ranks #777 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 95.7%.
Is China Isotope & Radiation's Receivables Turnover too high?
China Isotope & Radiation's current Receivables Turnover is 0.88. The Medical Devices & Instruments industry median Receivables Turnover is 5.60. China Isotope & Radiation's value of 0.88 is 84.3% below this industry median. Based on the distribution chart, China Isotope & Radiation ranks #777 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, China Isotope & Radiation has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Isotope & Radiation's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, China Isotope & Radiation ranks #777 out of 812 companies for Receivables Turnover. This places China Isotope & Radiation in the lower half of its industry. The industry median Receivables Turnover is 5.60. China Isotope & Radiation's value of 0.88 is 84.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.60, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Isotope & Radiation's current Receivables Turnover of 0.88 is 84.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on China Isotope & Radiation and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Isotope & Radiation's current Receivables Turnover is 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Isotope & Radiation stock overvalued right now?
China Isotope & Radiation (FRA:5IR) has a current Receivables Turnover of 0.88. The stock's GF Value™ is €1.63, compared to a current price of €1.77 — trading 8.6% above its estimated fair value. The current Receivables Turnover is 0.88 and 84.3% below the Medical Devices & Instruments industry median of 5.60. China Isotope & Radiation's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For China Isotope & Radiation (FRA:5IR), the current Receivables Turnover is 0.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Isotope & Radiation (FRA:5IR) Overvalued in 2026?
Based on GuruFocus' analysis, China Isotope & Radiation stock appears to be overvalued.
The current stock price of €1.77 is trading 8.6% above its estimated GF Value™ of €1.63.
Key valuation signals for FRA:5IR:
Receivables Turnover: 0.88
GF Value™: €1.63 vs. price of €1.77 (8.6% above fair value)
Industry Position: 84.3% below the Medical Devices & Instruments median (#777 of 812)
No single metric tells the full story. See the FRA:5IR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: (1) nuclear medicine; (2) radioactive source products; (3) irradiation; (4) nuclear medical equipment and related services; and (5) other businesses. Nuclear medicines: manufacturing and sale of a range of imaging diagnostic and therapeutic radio pharmaceuticals imaging, UBT diagnostic kits and test analysers and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The company's operations are carried out and a majority of its customers are located in the PRC.
92GF Score
Get the complete analysis for FRA:5IR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5IR has been successfully added to your 
